School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.
Thromb Haemost. 2024 Feb;124(2):152-162. doi: 10.1055/a-2107-0815. Epub 2023 Jun 7.
Venous thromboembolism (VTE) is associated with increased morbidity, mortality, and health care expenditure. However, the comprehensive utilization of anticoagulation therapy in patients with VTE, especially regarding active cancer, in real-world practice remains unclear.
To describe the prescription, persistence, and patterns of anticoagulation therapy among patients with VTE stratified according to active cancer.
Using Korean nationwide claims data, we identified an incident, treatment-naïve cohort of patients with VTE from 2013 to 2019 and classified them according to the presence/absence of active cancer. We explored the secular trends, treatment patterns (e.g., discontinuation, interruption, and switch), and persistence of anticoagulation therapy.
There were 48,504 and 7,255 patients without and with active cancer, respectively. Non-vitamin K antagonist oral anticoagulants (NOACs) were the most common anticoagulant in both groups (65.1 and 57.9%, respectively). The prescription of NOACs increased steeply over time, regardless of active cancer, whereas parenteral anticoagulants (PACs) plateaued and warfarin decreased sharply. A heterogeneous pattern was observed between the groups without and with active cancer (3-month persistence was 60.8, 62.9, 57.2, and 3.4%, respectively; 6-month persistence was 42.3, 33.5, 25.9, and 1.2% vs. 9.9%). Median durations of continuous anticoagulant therapy for warfarin, NOAC, and PAC were 183, 147, and 3 days in nonactive cancer patients, and 121, 117, and 44 days in active cancer patients.
Our findings suggest that there were substantial differences in persistence, patterns, and patient characteristics of anticoagulant therapy based on index anticoagulant and active cancer.
静脉血栓栓塞症(VTE)与发病率、死亡率和医疗保健支出增加有关。然而,在真实世界的实践中,VTE 患者,特别是患有活动性癌症的患者,对抗凝治疗的综合利用情况仍不清楚。
根据活动性癌症,描述 VTE 患者的抗凝治疗方案、持续时间和模式。
利用韩国全国性的索赔数据,我们从 2013 年至 2019 年确定了一个 VTE 的初治、无治疗经验的队列,并根据是否存在活动性癌症对其进行分类。我们探讨了抗凝治疗的时间趋势、治疗模式(如停药、中断和换药)和持续性。
分别有 48504 名和 7255 名患者无和有活动性癌症。在两组中,非维生素 K 拮抗剂口服抗凝剂(NOACs)都是最常用的抗凝剂(分别为 65.1%和 57.9%)。无论是否有活动性癌症,NOAC 的处方量都在急剧增加,而普通肝素(UFH)和低分子肝素(LMWH)则趋于平稳,华法林则急剧下降。无和有活动性癌症两组之间存在异质模式(3 个月的持续性分别为 60.8%、62.9%、57.2%和 3.4%;6 个月的持续性分别为 42.3%、33.5%、25.9%和 1.2%)。非活性癌症患者中,华法林、NOAC 和普通肝素的连续抗凝治疗中位持续时间分别为 183 天、147 天和 3 天,而在活性癌症患者中分别为 121 天、117 天和 44 天。
我们的研究结果表明,根据索引抗凝剂和活动性癌症,抗凝治疗的持续性、模式和患者特征存在显著差异。